Posts tagged Peptides
FDA’s PCAC Votes in Favor of Six Peptides for Potential Inclusion on the 503A Bulks List: What Compounders Need to Know
FDA’s PCAC Votes in Favor of Six Peptides for Potential Inclusion on the 503A Bulks List: What Compounders Need to Know

On July 23-24, 2026, the U.S. Food and Drug Administration’s (FDA’s) Pharmacy Compounding Advisory Committee (PCAC) met to consider seven peptide-related bulk drug substances for potential inclusion on the 503A Bulks List. PCAC voted in favor of including the free-base and acetate forms of BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax, while voting against inclusion of Emideltide (DSIP). Vote outcomes were the same for the free-base and acetate forms of each substance. With peptide compounding at an important regulatory crossroads, it is worth unpacking what occurred during the July 2026 meeting, what the committee’s votes mean today, and what questions remain as FDA considers the next steps in the regulatory process.

Read More
503A, 503BAna AleksicPeptides, Compounding, Compounding Bulk Drug Substances
Peptide Compounding Potency Challenges: Key Considerations for Pharmacies
Peptide Compounding Potency Challenges: Key Considerations for Pharmacies

Many compounders approach peptide compounding as a variation of small-molecule compounding they have performed for years. Then a batch that passed potency testing at release begins to decline (or mysteriously increase) during stability testing. In other cases, a formulation that performed well during development shows variable concentrations during routine production. Rather than searching for who is at fault, a more useful approach is to ask when the measurable intact drug began to change. This requires looking at the entire system to find the answers. 

Read More
503A, 503BAna AleksicCompounding, Peptides
FDA Peptides Meeting July 2026: What Happens After the PCAC Vote
FDA Peptides Meeting July 2026: What Happens After the PCAC Vote

On July 23–24, 2026, FDA’s Pharmacy Compounding Advisory Committee (PCAC) will review seven peptides for potential inclusion on the 503A Bulks List. This discussion extends beyond headlines about “popular unproven chemicals.” It is a regulatory and drug safety matter with direct implications for compounders and patients nationwide. We examine which peptides will be reviewed, the regulatory steps that follow the PCAC meeting, and what the outcome could mean for patient access and the broader future of personalized medicine.

Read More
503A, 503BAmy SummersPeptides, Compounding, Compounding Bulk Drug Substances